Related Experiment Video
Updated: Jul 12, 2025
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
[Acute myeloid leukemia. Analysis of 114 patients]
Nicolás Triantafilo1, Mauricio Sarmiento1, James Campbell1
1Hematología, Red de Salud UCChristus, Santiago, Chile.
Background:
Acute myeloid leukemia (AML) is the most common leukemia in adults.
Aim:
To Describe our population of patients with AML and report the outcomes of our treatments.
Material And Methods:
Review of electronic clinical records of 114 patients with AML with a median age of 57 years (59% men).
Results:
Seventeen percent of patients were classified as low risk, 38% as intermediate risk and 33% as high risk. Seventy-six percent of patients were treated with intensive chemotherapy. Five years overall survival according to cytogenetic risk was 59, 41, and 12% in low, intermediate, and high-risk patients, respectively. The outcomes were better in patients under 60 years. The median survival of patients treated with intensive chemotherapy aged less than 60 years and 60 years and above was 3.4 and 1 year, respectively.
Conclusions:
Our results are comparable to those reported in developed countries. Improving the survival of patients 60 years and older is our main challenge.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
